FORGE Life Science is now Evrys Bio. Read more
FORGE Life Science secures $1.0 M in bridge financing from its strategic investors.
FORGE Life Science Head of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address Respiratory Viruses”, at the 6th International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference – Advanced Respiratory Virus Therapeutics, Rockville, MD.
FORGE Life Science is awarded its first Department of Defense STTR contract (W911QY18P0300) from the Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical Countermeasure Against Marburg Virus”.
FORGE Life Science CEO, Lillian Chiang, presents at the National Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment.
The European Patent Office grants patent EP 2670404 B1, allowing claims directed to antiviral treatments with inhibitors of two or more sirtuins. This I.P. is exclusively licensed by FORGE from Princeton University. Read more
FORGE Life Science CEO, Lillian Chiang, presents at the Military Health System Research Symposium, Kissimmee, FL. Read more
Life Science completes its Phase I milestones and receives a Notice of Award for the Phase II component of its FastTrack SBIR grant titled, “Sirtuin Agonists as Pan Influenza Antivirals” (4R44AI122488-02). Read more
FORGE Life Science enters into a Sponsored Research Agreement with St. Jude Children’s Research Hospital. FORGE will collaborate with Drs. Richard J. Webby and Elena Govorkova to study the effect of FORGE host-targeted antivirals in ferret models of respiratory infection.
FORGE Life Science enters into a Cooperative Research & Development Agreement with the U.S. Army Medical Research Institute of Infectious Disease to test FORGE host-targeted antivirals against Department of Defense priority pathogens such as Marburg virus, Venezuelan equine encephalitis virus, and Lassa virus.
FORGE Life Science President & CEO, Lillian Chiang, is selected to join Springboard Enterprises Health Innovation Hub 2018: Life Sciences Track cohort for women entrepreneurs. Read more
FORGE Life Science completes Milestone 1 in agreement with BioArdis, LLC, securing second tranche of in-kind services investment.
FORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.
FORGE Life Science President & CEO, Lillian Chiang, presents “Targeting Host-cell Metabolism to Address Multiple Intracellular Pathogens” at the 2017 Chemical and Biological Defense Science & Technology Conference, Long Beach, CA. Read more
FORGE Life Science secures a second in-kind services investment from BioArdis, LLC, expanding FORGE medicinal chemistry and DMPK research resources to include BioDuro, global provider of contract research services.
FORGE Life Science Board of Directors meeting with new external members Richard J. Whitley, Brian Pusch, Steven Holtzman joining Founders Thomas E. Shenk and Lillian W. Chiang on the Board.
FORGE Life Science President & CEO, Lillian Chiang, presents at 9th Annual Biotech Showcase 2017 investor conference in San Francisco, CA.
FORGE Life Science Board Chairman, Thomas Shenk, presents at China Renaissance’s 4th Healthcare and Life Sciences Leadership Summit in Shanghai, China.
BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more.
BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more
FORGE Life Science named one of 2016’s Best University Startups by the National Council of Entrepreneurial Tech Transfer (NCET2). Read more
FORGE Life Science is awarded its fourth grant from the NIH National Institute for Allergy and Infectious Disease titled, ”Sirtuin Agonists as Pan-Influenza Antivirals” (1R44AI122488-01). Read more
Mid Atlantic Bio Angels chooses FORGE Life Science for its first Closed-End Investing Pool investment. Read more
FORGE Life Science secures an in-kind services investment from ShangPharma Investment Group Limited providing FORGE medicinal chemistry and DMPK contract research services from the service division of the ShangPharma group, ChemPartner, a leading contract research organization.
FORGE Life Science Board Chairman, Thomas Shenk is keynote speaker at the BioCentury China Healthcare Summit in Shanghai, China. His talk, “Been There, Done That, Doing It Again” tells his personal story as a serial entrepreneur from ImClone Systems to FORGE Life Science.
Dr. Eain Murphy, formerly Associate Professor of Virology at the Cleveland Clinic Lerner Research Institute, joins FORGE Life Science as Head of Biology.
FORGE Life Science is awarded its third grant from the NIH National Institute for Allergy and Infectious Disease titled, “An Antiviral to Treat Progressive Multifocal Leukoencephalopathy (PML)” (1R43AI118232-01). Read more
FORGE Life Science Founders, Ileana Cristea, Emre Koyuncu, and Thomas Shenk publish their breakthrough discovery that “Sirtuins Are Evolutionarily Conserved Viral Restriction Factors”. Read more
FORGE Life Science receives JumpStart Award announced at PA BIO Life Sciences Futures annual meeting in Philadelphia, PA. Read more
FORGE Life Science featured in the Innovator’s Corner of PharmaVoice magazine. Read more
Dr. Stacy Remiszewski, former Director of Chemistry, Section Head for Oncology Chemistry at Hoffmann-La Roche, joins FORGE Life Science as Head Of Chemistry.
FORGE Life Science LLC is awarded a second grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (1R43AI114079-01). Read more
FORGE Life Science LLC grant titled, “Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenza”, is awarded by the NIH National Institute for Allergy and Infectious Diseases (1R43AI110048-01). Read more
FORGE Life Science LLC exclusively licenses Sirtuin-Antiviral Technology from Princeton University.
FORGE Life Science LLC leases BSL2+ facilities from the Pennsylvania Biotechnology Center.